Filing Details
- Accession Number:
- 0001181431-12-049908
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2012-09-11 17:40:50
- Reporting Period:
- 2012-09-07
- Filing Date:
- 2012-09-11
- Accepted Time:
- 2012-09-11 17:40:50
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
873303 | Sarepta Therapeutics Inc. | SRPT | Pharmaceutical Preparations (2834) | 930797222 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1223756 | R Anthony Chase | 3450 Monte Villa Parkway, Suite 101 Bothell WA 98021 | Yes | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2012-09-07 | 13,300 | $13.95 | 56,944 | No | 4 | S | Direct | |
Common Stock | Disposition | 2012-09-07 | 19,700 | $14.79 | 37,244 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct | |
No | 4 | S | Direct |
Footnotes
- This transaction was executed in multiple trades in prices ranging from $13.55 to $14.525, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- This transaction was executed in multiple trades in prices ranging from $14.54 to $15.015, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.